Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by AVROBIO, Inc. < Previous 1 2 Next > AVROBIO and Tectonic Therapeutic Announce Merger January 30, 2024 From AVROBIO, Inc. Via Business Wire Tickers AVRO AVROBIO to Explore Strategic Alternatives July 12, 2023 From AVROBIO, Inc. Via Business Wire Tickers AVRO AVROBIO Completes Sale of Cystinosis Gene Therapy Program for $87.5 Million June 12, 2023 From AVROBIO, Inc. Via Business Wire Tickers AVRO AVROBIO Announces Agreement to Sell Cystinosis Gene Therapy Program for $87.5 Million May 22, 2023 From AVROBIO, Inc. Via Business Wire Tickers AVRO AVROBIO Announces Positive Data from Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis at the ASGCT 26th Annual Meeting May 18, 2023 From AVROBIO, Inc. Via Business Wire Tickers AVRO AVROBIO Reports First Quarter 2023 Financial Results and Provides Business Update May 11, 2023 From AVROBIO, Inc. Via Business Wire Tickers AVRO AVROBIO Announces Leadership Transition May 01, 2023 From AVROBIO, Inc. Via Business Wire Tickers AVRO AVROBIO Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Business Update March 23, 2023 From AVROBIO, Inc. Via Business Wire Tickers AVRO AVROBIO to Participate in Cowen’s 43rd Annual Health Care Conference March 03, 2023 From AVROBIO, Inc. Via Business Wire Tickers AVRO AVROBIO to Present Clinical and Preclinical Data from Lysosomal Disorder Gene Therapy Pipeline at WORLDSymposium™ 2023 February 09, 2023 From AVROBIO, Inc. Via Business Wire Tickers AVRO AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) January 05, 2023 From AVROBIO, Inc. Via Business Wire Tickers AVRO AVROBIO Announces New Positive Clinical Data and Outlines Clinical Development Plan Following Regulatory Discussions for its Gaucher Disease Gene Therapy December 07, 2022 From AVROBIO, Inc. Via Business Wire Tickers AVRO AVROBIO to Share Comprehensive Gaucher Disease Program Update November 17, 2022 From AVROBIO, Inc. Via Business Wire Tickers AVRO AVROBIO Reports Third Quarter 2022 Financial Results and Provides Business Update November 08, 2022 From AVROBIO, Inc. Via Business Wire Tickers AVRO AVROBIO to Participate in the Sixth Annual Barclays Gene Editing/Therapy Summit November 07, 2022 From AVROBIO, Inc. Via Business Wire Tickers AVRO AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) November 03, 2022 From AVROBIO, Inc. Via Business Wire Tickers AVRO AVROBIO Receives Rare Pediatric Disease Designation from the U.S. FDA for First-in-Class Gene Therapy for Gaucher Disease October 27, 2022 From AVROBIO, Inc. Via Business Wire Tickers AVRO AVROBIO Announces Completion of Patient Dosing in First Gene Therapy Clinical Trial for Cystinosis October 25, 2022 From AVROBIO, Inc. Via Business Wire Tickers AVRO AVROBIO Granted ILAP Designation from U.K. MHRA for First-in-Class Gene Therapy for Gaucher Disease October 18, 2022 From AVROBIO, Inc. Via Business Wire Tickers AVRO AVROBIO Reports Favorable Data on Use of Combined State-of-the-art In Vitro Cell-based Assays to Identify Potential Genotoxicity Risk of Integrating Vectors During Preclinical Development October 11, 2022 From AVROBIO, Inc. Via Business Wire Tickers AVRO AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) October 06, 2022 From AVROBIO, Inc. Via Business Wire Tickers AVRO AVROBIO to Present New Preclinical Data on Vector Safety at ESGCT Annual Congress September 27, 2022 From AVROBIO, Inc. Via Business Wire Tickers AVRO AVROBIO Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration (FDA) for First Gene Therapy in Development for Cystinosis September 20, 2022 From AVROBIO, Inc. Via Business Wire Tickers AVRO AVROBIO Announces Neuronopathic Mucopolysaccharidosis Type II (nMPS-II) or Hunter Syndrome Clinical Trial Application (CTA) Accepted by U.K. Regulatory Agency to Initiate Pediatric Phase 1/2 Gene Therapy Trial September 14, 2022 From AVROBIO, Inc. Via Business Wire Tickers AVRO AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) September 08, 2022 From AVROBIO, Inc. Via Business Wire Tickers AVRO AVROBIO to Participate in Four Upcoming Investor Conferences in September August 31, 2022 From AVROBIO, Inc. Via Business Wire Tickers AVRO AVROBIO Reports Second Quarter 2022 Financial Results and Provides Business Update August 09, 2022 From AVROBIO, Inc. Via Business Wire Tickers AVRO AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) August 04, 2022 From AVROBIO, Inc. Via Business Wire Tickers AVRO AVROBIO to Participate in Two Upcoming Investor Conferences in August August 01, 2022 From AVROBIO, Inc. Via Business Wire Tickers AVRO AVROBIO Receives Orphan Drug Designation from the U.S. Food and Drug Administration for AVR-RD-05, a Gene Therapy for Mucopolysaccharidosis Type II (MPSII) or Hunter Syndrome July 13, 2022 From AVROBIO, Inc. Via Business Wire Tickers AVRO < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
